United States Patent and Trademark Office UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov PPLICATION NO. FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/681,103 10/09/2003 Dehou Fei 7590 03/29/2007 Dehou Fei **EXAMINER** Apt. 2H PAK, JOHN D 3736 10th Ave. New York, NY 1003 ART UNIT PAPER NUMBER 1616

Please find below and/or attached an Office communication concerning this application or proceeding.

8125

DELIVERY MODE

PAPER

MAIL DATE

03/29/2007

Art Unit: 1616

This Office communication is in response to applicant's letter of March 22, 2007.

The Office regrets the delay that applicant references.

The Notice of Non-Compliant Amendment (37 CFR 1.121) mailed on 8/31/2005 is hereby rescinded as being incomplete.

Applicant was advised as follows in the Office action of June 21, 2005 -

Applicant is advised that a patent claim in U.S. practice must contain only 1 sentence. All of applicant's claims contain many sentences. This is improper.

An examination of this application reveals that applicant is unfamiliar with patent prosecution procedure. While an inventor may prosecute the application, tack of skill in this field usually acts as a liability in affording the maximum protection for the invention disclosed. Applicant is advised to secure the services of a registered patent attorney or agent to prosecute the application, since the value of a patent is targety dependent upon skilled preparation and prosecution. The Office cannot aid in selecting an attorney or agent.

On July 8, 2005, applicant was given an opportunity to speak with the Patent Examiner of this application. The Examiner provided an explanation of procedure and PTO resource, and faxed two example U.S. Patents so that applicant may better comprehend how to write an acceptable U.S. Patent claim. See the Interview Summary Record.

On July 25, 2005, applicant filed amendments that are not in accordance with the Patent Office rules and regulations. On August 2, 2005, a Notice of Non-Compliant Amendment was mailed to applicant. On August 24, 2005, applicant another amendment that was again not in accordance with the Patent Office rules and regulations. On August 31, 2005, another Notice of Non-Compliant Amendment was

Art Unit: 1616

mailed to applicant. Unfortunately, this second Notice did not explain the non-compliant problem. Nonetheless, there is no record of applicant having replied to this second Notice of Non-Compliant Amendment.

That is where this application stands as of this writing. In view of the fact that the second Notice of August 31, 2005 did not explain the defects in applicant's previous amendment, this Office action is a supplemental action thereto.

Applicant's most recent amendment, filed on August 24, 2005, is a non-compliant attempt to amend the claims and the specification.

Applicant is advised to follow these directions to correct the non-compliance:

- (1) On a separate page, write, "In response to the Restriction requirement of June 21, 2005, I elect Group III."
- (2) **On another separate page**, write the following, exactly as shown, and fill in as necessary where indicated --

IN THE CLAIMS:

Claims 1-4 (canceled).

Claim 5. (New) ** write one sentence that sets forth your elected invention **

Claim 6. (New) ** if another claim is needed, write one sentence **

Applicant is advised that the Examiner cannot comprehend what applicant intends as claim 5 from applicant's amendment of August 24, 2005. If applicant were to submit the following claims as new claims 5-6, the Examiner would find such claim

Art Unit: 1616

language to be at least compliant with the rules and regulations concerning amending the claims in proper form (but making no determination at this time as to patentability defects under 35 USC 102, 103 or 112) --

Claim 5. (New) A health pill for reducing the harmful effects of cigarette smoking comprising:

0.2 to 14.6 mg of sodium selenite;

3.5 to 67 ml of 1.85% β -cyclodextrin;

0.2 to 10 g of Vitamin E;

3 to 35 mg of Vitamin A;

0.3 to 27 mg of butylated hydroxytoluene;

7 to 200 mg of riboflavin;

7 to 200 mg of nicotinic acid; and

33 to 2000 mg of pyridoxine hydrochloride.

Claim 6. (New) The health pill of claim 5, further comprising 0.07 to 6 g of ascorbic acid.

At this time, <u>applicant is requested to NOT make any further amendments to the specification, because it is clear that applicant does not understand how to accomplish that task without triggering another non-compliance.</u> Once applicant has filed a

Art Unit: 1616

compliant response by following the above directions and examination of the case can proceed, applicant may contact the Examiner to address this issue.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to JOHN PAK whose telephone number is (571)272-0620. The Examiner can normally be reached on Monday to Friday from 8 AM to 4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's SPE, Johann Richter, can be reached on (571)272-0646.

The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1616

Page 6

Primary Examiner Technology Center 1600